Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP General Counsel and Secret | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,373 |
Ending reported balance
After 2026-08-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-19 · Exercise / conversion · Acquired 12,282 · Balance 45,392 Row 2 · 2026-08-19 · Tax withholding · Disposed 9,019 · Balance 36,373 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $381.92 · Expires 2026-12-16 | Direct | 12,283 |
Reported balance
After 2026-08-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-19 · Exercise / conversion · Disposed 12,282 · Balance 12,283 F1: The stock option award vested in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 2024 GRAT | 3,402 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,402 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 5,407 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,407 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 413 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 413 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Merck & Co., Inc.
Report date November 17, 2003 · Filed November 18, 2003
Section 16 reporting ended · disclosed 2003-11-18. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $59.20 | $0.00 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · derivative · entry 24 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,933 Underlying: Common Stock · 5,000 shares Expires 2021-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $59.20 | $0.00 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · derivative · entry 23 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,933 Underlying: Common Stock · 5,000 shares Expires 2021-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $59.20 | $0.00 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · derivative · entry 22 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,933 Underlying: Common Stock · 5,000 shares Expires 2021-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,689 | $488.22 | $1,312,823.58 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 6 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,235 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $59.20 | $296,000.00 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 5 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,757 | $488.22 | $1,346,022.54 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 4 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,924 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $59.20 | $296,000.00 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 3 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,757 | $488.22 | $1,346,022.54 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,681 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $59.20 | $296,000.00 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 24,500 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001237899-19-000035 · edgardoc.xml · derivative · entry 3 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2029-12-11 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000035 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,438 F1 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 11, 2021 and 50% on December 11, 2023. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001237899-18-000020 · edgardoc.xml · derivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · SVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 23,337 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001237899-17-000031 · edgardoc.xml · derivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · SVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,337 Underlying: Common Stock · 23,337 shares Expires 2027-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 24,565 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000093 · edgardoc.xml · derivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · SVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,565 Underlying: Common Stock · 24,565 shares Expires 2026-12-16 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.